Replimune Group, Inc.: Form 10-K for the period ended Mar 31, 2024
Filed with the SEC on May 16, 2024 and accepted by EDGAR at May 16, 2024, 08:14 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2023-04-01 to 2024-03-31 | $175.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-04-01 to 2024-03-31 | −$234.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2023-04-01 to 2024-03-31 | $408.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-04-01 to 2024-03-31 | −$215.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-04-01 to 2024-03-31 | −$3.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-04-01 to 2024-03-31 | −$3.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-04-01 to 2024-03-31 | 66,569,894 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-04-01 to 2024-03-31 | −$185.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-04-01 to 2024-03-31 | $5.7m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2024-03-31 | $74.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $433.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $487.7m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $40.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $113.2m | us-gaap:Liabilities |
| Long-term debt | At period end2024-03-31 | $44.8m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2024-03-31 | $374.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001737953-24-000008. Last ingested by Listed: Oct 28, 2026, 07:26 ET. Listed shows no prices and gives no investment advice.